Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.

McNicholas P, Vilchez RA, Greaves W, Kumar S, Onyebuchi C, Black T, Strizki JM.

J Clin Virol. 2012 Oct;55(2):134-9. doi: 10.1016/j.jcv.2012.06.021. Epub 2012 Jul 21.

PMID:
22824230
2.

Application of affinity selection-mass spectrometry assays to purification and affinity-based screening of the chemokine receptor CXCR4.

Whitehurst CE, Yao Z, Murphy D, Zhang M, Taremi S, Wojcik L, Strizki JM, Bracken JD, Cheng CC, Yang X, Shipps GW Jr, Ziebell M, Nickbarg E.

Comb Chem High Throughput Screen. 2012 Jul;15(6):473-85.

PMID:
22651846
3.

Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).

McNicholas PM, Mann PA, Wojcik L, Qiu P, Lee E, McCarthy M, Shen J, Black TA, Strizki JM.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):222-9. doi: 10.1097/QAI.0b013e3181ff63ee.

PMID:
21209592
4.

Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial.

McNicholas P, Wei Y, Whitcomb J, Greaves W, Black TA, Tremblay CL, Strizki JM.

J Infect Dis. 2010 May 15;201(10):1470-80. doi: 10.1086/652189.

PMID:
20373959
5.

Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor.

Buontempo PJ, Wojcik L, Buontempo CA, Ogert RA, Strizki JM, Howe JA, Ralston R.

Virology. 2009 Dec 20;395(2):268-79. doi: 10.1016/j.virol.2009.09.029. Epub 2009 Oct 20.

6.

A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.

Pett SL, McCarthy MC, Cooper DA, MacRae K, Tendolkar A, Norris R, Strizki JM, Williams KM, Emery S.

Antivir Ther. 2009;14(1):111-5.

PMID:
19320244
7.

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.

Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou CC, Pugliese-Sivo C, Xiao Y, Tagat JR, Cox K, Priestley T, Sorota S, Huang W, Hirsch M, Reyes GR, Baroudy BM.

Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9.

9.

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.

Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT, Wolinsky SM, Moore JP.

J Virol. 2004 Mar;78(6):2790-807. Erratum in: J Virol. 2005 Jun;78(12):6706.

10.

Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.

Ketas TJ, Klasse PJ, Spenlehauer C, Nesin M, Frank I, Pope M, Strizki JM, Reyes GR, Baroudy BM, Moore JP.

AIDS Res Hum Retroviruses. 2003 Mar;19(3):177-86.

PMID:
12689409
11.

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides.

McCombie SW, Tagat JR, Vice SF, Lin SI, Steensma R, Palani A, Neustadt BR, Baroudy BM, Strizki JM, Endres M, Cox K, Dan N, Chou CC.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):567-71.

PMID:
12565973
12.

Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.

Palani A, Shapiro S, Josien H, Bara T, Clader JW, Greenlee WJ, Cox K, Strizki JM, Baroudy BM.

J Med Chem. 2002 Jul 4;45(14):3143-60.

PMID:
12086500
13.

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.

Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, Moore JP.

Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):395-400.

14.

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Shapiro S, Clader JW, Greenlee WJ, Tagat JR, McCombie S, Cox K, Fawzi AB, Chou CC, Pugliese-Sivo C, Davies L, Moreno ME, Ho DD, Trkola A, Stoddart CA, Moore JP, Reyes GR, Baroudy BM.

Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12718-23. Epub 2001 Oct 16.

15.
16.

CXCR-4 (Fusin), a co-receptor for the type 1 human immunodeficiency virus (HIV-1), is expressed in the human brain in a variety of cell types, including microglia and neurons.

Lavi E, Strizki JM, Ulrich AM, Zhang W, Fu L, Wang Q, O'Connor M, Hoxie JA, González-Scarano F.

Am J Pathol. 1997 Oct;151(4):1035-42.

18.

Use of primary CNS cultures to investigate HIV neurotropism.

González-Scarano F, Strizki JM, Albright A, Shieh J.

J Neurovirol. 1997 May;3 Suppl 1:S11-3. No abstract available.

PMID:
9179782
19.

Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism.

Strizki JM, Albright AV, Sheng H, O'Connor M, Perrin L, González-Scarano F.

J Virol. 1996 Nov;70(11):7654-62.

21.
22.

Structural protein relationships among eastern equine encephalitis viruses.

Strizki JM, Repik PM.

J Gen Virol. 1994 Nov;75 ( Pt 11):2897-909.

PMID:
7964601

Supplemental Content

Loading ...
Support Center